Clinical Trial

A Phase Ⅰ Clinical Trial to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of SHR-3045 in Healthy Subjects

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR-3045 in healthy subjects.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-13; most recent amendment 2026-06-04.
Status change: Active, Not Recruiting → Completed 2026-06-04
Status change: Recruiting → Active, Not Recruiting 2025-08-11
Status change: Not Yet Recruiting → Recruiting 2025-04-24
Trial Details
NCT Number NCT06883695
Lead Sponsor Guangdong Hengrui Pharmaceutical Co., Ltd
Conditions Rheumatoid Arthritis
Enrollment 40 participants
Start Date 2025-04-08
Primary Completion 2025-06-17 (estimated)
Study Completion 2025-10-10 (estimated)
Updated on ClinicalTrials.gov 2026-06-05